BMRN vs RGLD · P/E 40, rev $1.76B vs P/E 26, rev $919.7M
Biomarin Pharmaceutical Inc (BMRN) versus Royal Gold Inc (RGLD) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Royal Gold Inc (RGLD) is a gold company listed on NASDAQ.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported RGLD revenue for 2026-06-30 was $919.7M. Net income was $517.5M. Revenue was up 96.0% from 2026-03-31 to 2026-06-30. RGLD currently screens at market cap $18.54B and trailing P/E 26.4.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. RGLD currently screens at market cap $18.54B and trailing P/E 26.4.
Not investment advice. Open the BMRN and RGLD stock pages for the full models.
Not investment advice.